• Nilotinib (AMN-107): Deciphering Tyrosine Kinase Inhibiti...

  2025-10-24

  Explore how Nilotinib (AMN-107), a selective BCR-ABL inhibitor, is revolutionizing chronic myeloid leukemia research by enabling systems-level interrogation of kinase-driven tumor models. Discover unique insights into in vitro evaluation strategies and mechanistic profiling not covered elsewhere.

• Nilotinib: Advanced Applications in BCR-ABL Signaling and...

  2025-10-23

  Nilotinib (AMN-107) stands out as a next-generation selective tyrosine kinase inhibitor, uniquely tailored for dissecting the complexities of kinase-driven tumor models. This article details optimized experimental workflows, troubleshooting strategies, and comparative advantages that make Nilotinib indispensable for chronic myeloid leukemia and gastrointestinal stromal tumor research.

• 2-Deoxy-D-glucose: Metabolic Checkpoint Targeting in Tumo...

  2025-10-22

  Unlock the advanced potential of 2-Deoxy-D-glucose as a glycolysis inhibitor and metabolic oxidative stress inducer. Explore how 2-DG uniquely intersects with tumor immunometabolism, ATP synthesis disruption, and emerging immunotherapeutic strategies.

• LY2603618: Unveiling New Frontiers in Chk1 Inhibition and...

  2025-10-21

  Explore how LY2603618, a selective Chk1 inhibitor, is revolutionizing research into DNA damage response and genome stability. This article uniquely integrates emerging insights on nuclear cGAS, L1 retrotransposition, and cancer therapy sensitization.

94 records 7/7 page Previous First page 上5页 67